NYSE Euronext Announces Trading Volumes for April 2013
NYSE Euronext Announces Trading Volumes for April 2013
Global Derivatives ADV Up 3% Year-over-Year, Excluding Bclear
European Derivatives ADV Declined 6% Year-over-Year, Excluding Bclear
U.S. Equity Options ADV Up 10% Year-over-Year and Up 15% Sequentially
European and U.S. Cash Equities ADV Declined Year-over-Year But Rebounded Sequentially
NEW YORK--(BUSINESS WIRE)-- NYSE Euronext (NYX) today announced trading volumes for its global derivatives and cash equities exchanges for April 20131. Global derivatives average daily volume ("ADV") of 7 million contracts, excluding Bclear in April 2013 increased 4% compared to April 2012, and decreased 3% from March 2013. U.S. equity options volumes rebounded in April 2013 with an increase of 10% compared to April 2012 and an increase of 15% from March 2013 levels. ADV in U.S. cash equities declined 10% year-over-year, but increased 2% month-over-month. European cash equities ADV in April 2013 decreased 20% compared to April 2012, but increased 8% from March 2013 levels.
- NYSE Euronext global derivatives ADV in April 2013 of 6.9 million contracts, excluding Bclear increased 3.2% compared to April 2012 and decreased 3.4% from March 2013 levels.
- NYSE Euronext European derivatives products ADV in April 2013 of 2.6 million contracts, excluding Bclear, decreased 5.8% compared to April 2012, and decreased 22.3% from March 2013 levels. Including Bclear, NYSE Liffe's trade administration and clearing service for OTC products, European derivatives ADV decreased 18.2% compared to April 2012 and decreased 18.0% from March 2013.
- NYSE Euronext U.S. equity options (NYSE Arca and NYSE Amex) ADV of 4.3 million contracts in April 2013 increased 10.1% compared to April 2012 levels and increased by 14.6% from March 2013 levels. NYSE Euronext's U.S. options exchanges accounted for 28.0% of total U.S. consolidated equity options trading in April 2013, up from 26.4% in April 2013.
- NYSE Liffe U.S. ADV of approximately 47,100 contracts decreased from 61,500 contracts in April 2012 and decreased from 78,100 contracts in March 2013.
- NYSE Euronext European cash products ADV of 1.5 million transactions in April 2013 decreased 19.8% compared to April 2012, but increased 7.5% compared to March 2013.
- NYSE Euronext U.S. cash products (NYSE, NYSE Arca and NYSE-MKT) handled ADV of 1.6 billion shares in April 2013 a decrease of 9.5% compared to April 2012, but increased 2.3% compared to March 2013. NYSE Euronext's Tape A matched market share in April 2013 was 30.2%, down from 31.3% in April 2012 and down from 31.1% in March 2013.
1 All NYSE Euronext derivatives transactions count buy and sell orders together as a single transaction. NYSE Euronext European equities transactions count each buy and sell order as separate transactions, NYSE Euronext U.S. equities transactions count buy and sell orders together as a single transaction.
Please click here for the Monthly Transaction Activity Data Table.
About NYSE Euronext
NYSE Euronext (NYX) is a leading global operator of financial markets and provider of innovative trading technologies. The company's exchanges in Europe and the United States trade equities, futures, options, fixed-income and exchange-traded products. With approximately 8,000 listed issues (excluding European Structured Products), NYSE Euronext's equities markets - the New York Stock Exchange, NYSE Euronext, NYSE MKT, NYSE Alternext and NYSE Arca - represent one-third of the world's equities trading, the most liquidity of any global exchange group. NYSE Euronext also operates NYSE Liffe, one of the leading European derivatives businesses and the world's second-largest derivatives business by value of trading. The company offers comprehensive commercial technology, connectivity and market data products and services through NYSE Technologies. NYSE Euronext is in the S&P 500 index. For more information, please visit: http://www.nyx.com.
Please follow us at:
CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS
This written communication contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as "may," "hope," "will," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential," "continue," "could," "future" or the negative of those terms or other words of similar meaning. You should carefully read forward-looking statements, including statements that contain these words, because they discuss our future expectations or state other "forward-looking" information. Forward-looking statements are subject to numerous assumptions, risks and uncertainties which change over time. ICE Group, ICE and NYSE Euronext caution readers that any forward-looking statement is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement.
Forward-looking statements include, but are not limited to, statements about the benefits of the proposed merger involving ICE Group, ICE and NYSE Euronext, including future financial results, ICE's and NYSE Euronext's plans, objectives, expectations and intentions, the expected timing of completion of the transaction and other statements that are not historical facts. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in ICE's and NYSE Euronext's filings with the U.S. Securities and Exchange Commission (the "SEC"). These risks and uncertainties include, without limitation, the following: the inability to close the merger in a timely manner; the inability to complete the merger due to the failure of NYSE Euronext stockholders to adopt the merger agreement or the failure of ICE stockholders to adopt the merger agreement or approve related proposals; the failure to satisfy other conditions to completion of the merger, including receipt of required regulatory and other approvals; the failure of the proposed transaction to close for any other reason; the possibility that any of the anticipated benefits of the proposed transaction will not be realized; the risk that integration of NYSE Euronext's operations with those of ICE will be materially delayed or will be more costly or difficult than expected; the challenges of integrating and retaining key employees; the effect of the announcement of the transaction on ICE's, NYSE Euronext's or the combined company's respective business relationships, operating results and business generally; the possibility that the anticipated synergies and cost savings of the merger will not be realized, or will not be realized within the expected time period; the possibility that the merger may be more expensive to complete than anticipated, including as a result of unexpected factors or events; diversion of management's attention from ongoing business operations and opportunities; general competitive, economic, political and market conditions and fluctuations; actions taken or conditions imposed by the United States and foreign governments or regulatory authorities; and adverse outcomes of pending or threatened litigation or government investigations. In addition, you should carefully consider the risks and uncertainties and other factors that may affect future results of the combined company, as are described in the section entitled "Risk Factors" in the joint proxy statement/prospectus filed by ICE Group with the SEC, and as described in ICE's and NYSE Euronext's respective filings with the SEC that are available on the SEC's web site located at www.sec.gov, including the sections entitled "Risk Factors" in ICE's Form 10-K for the fiscal year ended December 31, 2012, as filed with the SEC on February 6, 2013, and "Risk Factors" in NYSE Euronext's Form 10-K for the fiscal year ended December 31, 2012, as filed with the SEC on February 26, 2013. You should not place undue reliance on forward-looking statements, which speak only as of the date of this written communication. Except for any obligations to disclose material information under the Federal securities laws, ICE Group, ICE and NYSE Euronext undertake no obligation to publicly update any forward-looking statements to reflect events or circumstances after the date of this written communication.
IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND WHERE TO FIND IT
This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. In connection with the proposed transaction, ICE Group has filed with the SEC a registration statement on Form S−4, which the SEC has declared effective and which contains a joint proxy statement/prospectus with respect to the proposed acquisition of NYSE Euronext by ICE Group. The final joint proxy statement/prospectus will be delivered to the stockholders of ICE and NYSE Euronext. INVESTORS AND SECURITY HOLDERS OF BOTH ICE AND NYSE EURONEXT ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION CAREFULLY AND IN ITS ENTIRETY, INCLUDING ANY DOCUMENTS PREVIOUSLY FILED WITH THE SEC AND INCORPORATED BY REFERENCE INTO THE JOINT PROXY STATEMENT/PROSPECTUS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE IT WILL CONTAIN IMPORTANT INFORMATION REGARDING ICE, NYSE EURONEXT AND THE PROPOSED TRANSACTION. Investors and security holders may obtain a free copy of the joint proxy statement/prospectus, as well as other filings containing information about ICE and NYSE Euronext, without charge, at the SEC's website at http://www.sec.gov. Investors may also obtain these documents, without charge, from ICE's website at http://www.theice.com and from NYSE Euronext's website at http://www.nyx.com.
PARTICIPANTS IN THE MERGER SOLICITATION
ICE, NYSE Euronext and their respective directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the transactions contemplated by the Merger Agreement.
You can find information about ICE and ICE's directors and executive officers in ICE's Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the SEC on February 6, 2013, and ICE's proxy statement for its 2012 annual meeting of stockholders, as filed with the SEC on March 30, 2012.
You can find information about NYSE Euronext and NYSE Euronext's directors and executive officers in NYSE Euronext's Annual Report on Form 10-K for the year ended December 31, 2012, as filed with the SEC on February 26, 2013, NYSE Euronext's proxy statement for its 2012 annual meeting of stockholders, filed with the SEC on March 26, 2012.
Additional information about the interests of potential participants is included in the joint proxy statement/prospectus, and the other relevant documents filed by ICE and NYSE Euronext with the SEC.
Monthly Volume Summary
|Average Daily Volume||Total Volume||Average Daily Volume||Total Volume|
|(Unaudited; contracts in thousands)||% Chg vs.||% Chg vs.|
|Apr-13||Apr-12||% Chg||Apr-13||Apr-12||% Chg||YTD 2013||YTD 2012||YTD 2013||YTD 2012|
|Number of Trading Days - European Cash||21||19||21||19||83||83|
|Number of Trading Days - European Derivatives||21||19||21||19||83||83|
|Number of Trading Days - U.S. Markets||22||20||22||20||82||82|
|European Derivatives Products||3,493||4,270||-18.2||%||73,352||81,127||-9.6||%||4,256||20.1||%||353,288||18.7||%|
|of which Bclear||856||1,471||-41.8||%||17,981||27,945||-35.7||%||876||2.7||%||72,730||1.5||%|
|Total Fixed Income Products||1,753||1,792||-2.2||%||36,803||34,049||8.1||%||2,497||40.4||%||207,236||38.7||%|
|Short Term Interest Rate Products||1,621||1,665||-2.7||%||34,036||31,636||7.6||%||2,322||42.3||%||192,745||40.6||%|
|Medium and Long Term Interest Rate Products 1||132||127||3.7||%||2,768||2,414||14.7||%||175||19.2||%||14,491||17.8||%|
|Total Equity Products2||1,637||2,397||-31.7||%||34,379||45,538||-24.5||%||1,665||-1.2||%||138,181||-2.4||%|
|Individual Equity Products||1,142||1,847||-38.1||%||23,986||35,085||-31.6||%||1,135||-5.9||%||94,164||-7.1||%|
|Equity Index Products||495||550||-10.0||%||10,394||10,453||-0.6||%||530||10.9||%||44,017||9.5||%|
|of which Bclear||856||1,471||-41.8||%||17,971||27,945||-35.7||%||875||2.5||%||72,610||1.3||%|
|Individual Equity Products||786||1,409||-44.2||%||16,513||26,765||-38.3||%||765||-2.2||%||63,521||-3.4||%|
|Equity Index Products||69||62||11.8||%||1,458||1,180||23.5||%||109||55.6||%||9,088||53.7||%|
|U.S. Derivatives Products|